GTx, Inc. (GTXI) Announces Enobosarm Met pre-Specified Primary Efficacy Endpoint in Phase 2 for ER+/AR+ Breast Cancer
Tweet Send to a Friend
GTx, Inc. (Nasdaq: GTXI) announced that enobosarm achieved the pre-specified primary efficacy endpoint in the 9 mg dose cohort from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
